Li, Bob T <br/><br/>
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  08 2018 
 - 2532-2537 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2018.77.9777  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma of Lung--drug therapy<br/>Ado-Trastuzumab Emtansine<br/>Aged<br/>Antineoplastic Agents, Immunological--therapeutic use<br/>Female<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Maytansine--analogs & derivatives<br/>Middle Aged<br/>Mutation<br/>Receptor, ErbB-2--genetics<br/>Trastuzumab--therapeutic use<br/>Treatment Outcome